Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13224749 | 0.82 | PKM (0.47) | ALDH1A1MEN1GAAPKMKMT2A | |
| SCHEMBL1104960 | 0.76 | POLB (0.33) | ALDH1A1MEN1GAAPKMKMT2A | |
| SCHEMBL1104956 | 0.71 | MEN1 (0.31) | ALDH1A1MEN1GAAPKMKMT2A | |
| SCHEMBL1104961 | 0.69 | PKM (0.35) | ALDH1A1MEN1GAAPKMKMT2A | |
| SCHEMBL1104952 | 0.69 | ALDH1A1 (0.32) | ALDH1A1MEN1GAAPKMKMT2A | |
| SCHEMBL1104957 | 0.69 | ALDH1A1 (0.39) | ALDH1A1GAAPKMKMT2ASMN1; SMN2 | |
| SCHEMBL1104964 | 0.66 | CA2 (0.59) | ALDH1A1SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL1104955 | 0.64 | SMN1; SMN2 (0.59) | ALDH1A1MEN1GAAPKMKMT2A | |
| SCHEMBL1104972 | 0.64 | LMNA (0.59) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL1104968 | 0.59 | TDP1 (0.37) | ALDH1A1MEN1GAAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | ALDH1A1 1369/4885MEN1 4141/4885GAA 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.